



CHA₂DS₂-VASc Score in the Prediction of Ischemic Stroke in Patients after Radiofrequency Catheter Ablation of Typical Atrial Flutter

Moo-Nyun Jin, Changho Song, Tae-Hoon Kim, Jae-Sun Uhm,
Hui-Nam Pak, Moon-Hyoung Lee, and Boyoung Joung

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Despite undergoing successful catheter ablation of typical atrial flutter (AFL), patients remain at increased risk for ischemic stroke. However, data on risk prediction tools for the development of stroke after AFL ablation are lacking. This study investigates whether CHA₂DS₂-VASc score is useful for predicting ischemic stroke after successful ablation of typical AFL.

Materials and Methods: A total of 293 patients (236 men, mean age 56.1±13.5 years) who underwent successful radiofrequency catheter ablation for typical AFL were included in this study. The clinical end point was occurrence of ischemic stroke during follow-up after AFL ablation.

Results: During the follow-up period (60.8±45.9 months), ischemic stroke occurred in 18 (6%) patients at a median of 34 months (interquartile range, 13–65 months). CHA₂DS₂-VASc score [hazard ratio 2.104; 95% confidence interval (CI), 1.624–2.726; *p*<0.001] was an independent predictor for the occurrence of stroke after AFL ablation. The area under the receiver operating characteristic curve for CHA₂DS₂-VASc score was 0.798 (95% CI, 0.691–0.904). The CHA₂DS₂-VASc score could be used to stratify patients into two groups with different incidences of ischemic stroke (1.6% vs. 14.4%, *p*<0.001) at a cutoff value of 2.

Conclusion: CHA₂DS₂-VASc score is useful in a prediction model for the risk of stroke after catheter ablation of typical AFL.

Key Words: Atrial flutter, atrial fibrillation, stroke, catheter ablation, CHA₂DS₂-VASc score

INTRODUCTION

Atrial flutter (AFL) is associated with an increased risk of thromboembolism.^{1,2} Radiofrequency catheter ablation of AFL has a high success rate with rare complications. Thus, catheter ablation is generally accepted as a first-line treatment strategy for patients with typical AFL.³ Nonetheless, subsequent development of atrial fibrillation (AF) is common after AFL ablation. A prior meta-analysis reported that the overall incidence

of AF after AFL ablation was 33.6%, with an average follow-up of 15 months; however, 3 years after ablation, the incidence of AF was up to 56.6%.⁴ If no atrial arrhythmias are apparent, the prevalent practice is to stop anticoagulation one month after successful AFL ablation.⁵⁻⁷ As a result, a subset of patients who undergo catheter ablation of AFL may be at risk for thromboembolic complications, including ischemic stroke. Risk assessment using readily available clinical variables is the key to identify patients at increased risk of postablation stroke. Previous studies suggested that old age and postablation AF were risk factors of stroke;⁷⁻¹⁰ however, a predictor of stroke among patients with AFL who have undergone cavotricuspid isthmus (CTI) ablation have not been elucidated. No clear strategy addressing antithrombotic therapy after successful AFL ablation has emerged.

CHA₂DS₂-VASc score is a recommended risk stratification scheme for prediction of stroke or thromboembolism in non-valvular AF patients. Recently, this scoring system has been validated to have predictive capacity for outcomes in patients in

Received: May 10, 2017 **Revised:** August 28, 2017

Accepted: October 17, 2017

Corresponding author: Dr. Boyoung Joung, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

Tel: 82-2-2228-8460, Fax: 82-2-393-2041, E-mail: cby6908@yuhs.ac

•The authors have no financial conflicts of interest.

© Copyright: Yonsei University College of Medicine 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

different clinical situations. The aims of this study were to investigate predictors of stroke and whether CHA₂DS₂-VASc score is useful risk assessment tool for ischemic stroke in patients following successful AFL ablation.

MATERIALS AND METHODS

Study population

The subjects were consecutive patients who underwent successful catheter ablation for typical AFL at Severance Cardiovascular Hospital from October 2003 to January 2013. Typical AFL was diagnosed when a surface electrocardiogram (ECG) showed readily visible negative flutter wave in the inferior leads and positive flutter wave in lead V1 with a regular atrial rate.¹¹ Of the 387 patients enrolled, exclusion criteria were prior history of AF (n=68), moderate-to-severe valvular heart disease (n=15), hypertrophic cardiomyopathy (n=7), dilated cardiomyopathy (n=3), early recurrence less than 3 months (n=2), and follow-up period less than 6 months (n=4) (Fig. 1). Patient data including age, sex, comorbidities, use of medications, electrocardiographic findings, echocardiographic features, result of the ablation procedure, and follow-up information were collected. The CHA₂DS₂-VASc scores [congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack (TIA) (doubled), vascular disease, age 65 to 74 years, sex category] were calculated for each patient at the time of the ablation procedure. All signed written informed consent for the ablation procedures. Patients were enrolled prospectively in a longitudinal registry, and analysis was performed retrospectively. The study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System, Seoul, Korea (#4-2017-0937) and complied with the Declaration of Helsinki.

Electrophysiology study and catheter ablation

Antiarrhythmic drugs were discontinued for at least 5 half-lives

before ablation. Electrophysiological studies were performed in the postabsorptive state. Multipolar catheters were positioned as follows: 1) A duodecapolar catheter with 2-5-2 mm interelectrode was positioned in the right atrium (RA), parallel to the tricuspid annulus so that the distal pole was located in the medial region of the CTI. 2) A decapolar catheter was inserted within the coronary sinus, with the proximal bipole located at the ostium. 3) Quadripolar catheters were positioned at the His bundle and RA. Surface ECG and bipolar endocardial electrograms were monitored continuously and stored on a computer-based digital amplifier/recorder system with optical disk storage for offline analysis. Intracardiac electrograms were filtered from 30 Hz to 500 Hz and measured with computer-assisted calipers at a sweep. Ablation was typically started on the ventricular aspect of the CTI region, and sequential radiofrequency lesions were created extending from the tricuspid valve to the posterior aspect of the CTI. Ablation was deemed successful if AFL terminated during radiofrequency delivery, AFL was no longer inducible, and bidirectional CTI block was demonstrated.

Periprocedural anticoagulation strategy

Almost all patients were treated with warfarin to maintain an international normalized ratio between 2 and 3 for at least 3 weeks before the procedure, and continued to receive warfarin for at least 1 month after the procedure. After 1 month, decisions on continuing anticoagulation was determined at the physician's discretion, based on individual patient stroke risk factors. Antithrombotic drugs were administered according to characteristics of each patient.

Follow-up and clinical end point

The patients were monitored by continuous ECG recordings in a hospital for at least 24 hours. After discharge, all patients were followed up with clinical examination, 12-lead ECG, and 24-hour ambulatory Holter monitoring at 1, 3, 6, and 12 months after the procedure, and every 6 months thereafter. Subsequently, patients were seen every 3 to 6 months at our cardiology clinic. A successful outcome was defined as the absence of any atrial arrhythmia after the 3-month blanking period. New-onset AF was defined as symptomatic or asymptomatic AF documented by 12-lead ECG or ambulatory rhythm monitoring that lasted at least 30 seconds.¹² The clinical endpoint was an ischemic stroke, which was defined as onset of a new neurologic impairment that occurred after the ablation. Diagnosis of a stroke was confirmed by a neurologist, and correlated with cranial imaging evidence (computed tomography and/or magnetic resonance imaging). Stroke severity at baseline was assessed with the National Institutes of Health Stroke Scale (NIHSS) score by a neurologist.¹³ Etiology of ischemic stroke was classified into five categories by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification: 1) large-artery atherosclerosis, 2) cardioembolism, 3) small vessel occlusion, 4)




Fig. 1. Flow chart of the study population. *6 patients had VHD and AF, [†]2 patients had VHD, AF, and dilated cardiomyopathy, ^{††}1 patient had AF and hypertrophic cardiomyopathy. AFL, atrial flutter; AF, atrial fibrillation; VHD, valvular heart disease.

stroke of other determined etiology, and 5) stroke of undetermined etiology.¹⁴ Patients were censored at death, loss of follow-up, or end of study, whichever occurred first.

Statistical analysis

Continuous data are expressed as mean±standard deviation, and categorical variables are expressed as counts and percentages (%). Normality tests were performed for each variable to determine whether a dataset was well-modeled by normal distribution. Univariate comparisons were performed using Student’s t-test or Mann-Whitney U test for continuous variables, and chi-square test or Fisher’s test for categorical variables. Cox proportional hazards model was performed to identify predictors associated with ischemic strokes. Due to the small number of stroke events, multivariate Cox regression was performed using variables that had significant association with the risk for stroke by univariate analysis. The predictive accuracy of CHA₂DS₂-VASc score and the optimal cutoff value in the prediction of stroke after AFL ablation were identified using

receiver operating characteristic (ROC) curves and Youden index (sensitivity+specificity-1). Event free survival curves were plotted by the Kaplan-Meier method with the statistical significance tested by the log-rank test. Statistical significance was established at a value of *p*<0.05. Statistical analyses were performed with SPSS version 23.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Clinical characteristics and predictors of stroke after AFL ablation

A total of 387 patients were enrolled; 94 patients were excluded from the present study. The study population comprised 293 patients who underwent successful catheter ablation for typical AFL (Fig. 1). During the follow-up period of 60.8±45.9 months, ischemic strokes occurred in 18 (6%) patients. Median time to stroke occurrence was 34 months (interquartile range, 13–65 months) after ablation, and median NIHSS score on admission

Table 1. Comparison of Baseline Characteristics of Patients with and without Stroke after Catheter Ablation of AFL

Variable	Total population (n=293)	Stroke (n=18)	No stroke (n=275)	<i>p</i> value
Age (yr)	56.1±13.5	64.0±12.3	55.6±13.4	0.01
Age ≥65 yrs	71 (24.2)	12 (66.7)	59 (21.5)	<0.001
Age ≥75 yrs	12 (4.1)	5 (27.8)	7 (2.5)	<0.001
Female	58 (19.8)	1 (5.6)	57 (20.7)	0.216
Body mass index (kg/m ²)	23.9±3.1	24.0±2.7	23.9±3.1	0.913
Medical history				
Congestive heart failure	15 (5.5)	2 (11.1)	13 (4.7)	0.233
Hypertension	105 (35.8)	9 (50.0)	96 (34.9)	0.196
Diabetes mellitus	57 (19.5)	6 (33.3)	51 (18.5)	0.131
Prior stroke/TIA	15 (5.1)	5 (27.8)	10 (3.6)	0.001
Vascular disease	15 (5.1)	2 (11.1)	13 (4.7)	0.233
Coronary artery disease	36 (12.3)	4 (22.2)	32 (11.6)	0.254
Dyslipidemia	33 (11.3)	3 (16.7)	30 (10.9)	0.439
Echocardiogram characteristics				
LVEF (%)	61.5±10.3	60.3±9.1	61.6±10.4	0.619
LA diameter (mm)	41.9±6.1	44.2±6.3	41.7±6.1	0.112
LA volume index (mL/m ²)	34.4±12.5	38.8±14.9	34.2±12.2	0.197
Antithrombotic drugs use during follow-up period				
Antiplatelets after ablation	138 (47.1)	8 (44.4)	130 (47.3)	0.816
Warfarin after ablation	69 (23.5)	7 (38.9)	62 (22.5)	0.148
New-onset AF after ablation	96 (32.8)	12 (66.7)	84 (30.5)	0.002
Recurrence of AFL	8 (2.7)	2 (11.1)	6 (2.2)	0.08
CHA ₂ DS ₂ -VASc score	1.2±1.1	2.6±1.4	1.2±1.0	<0.001
0	85 (29)	1 (5.6)	84 (30.5)	
1	104 (35.5)	2 (11.1)	102 (58.3)	
2	67 (22.9)	7 (38.9)	60 (21.8)	
3	28 (9.6)	4 (22.2)	24 (8.7)	
≥4	9 (3.1)	4 (22.2)	5 (1.8)	

AF, atrial fibrillation; AFL, atrial flutter; CHA₂DS₂-VASc score, congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or TIA score, vascular disease and sex category; LA, left atrial; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack; SD, standard deviation. Values are given as n (%) or as mean±SD, unless otherwise noted.

for stroke was 2.5 (interquartile range, 1–6). Among 18 patients who developed stroke, the causes of stroke were as follows: cardioembolic stroke (n=15), large artery atherosclerosis (n=1), small-vessel occlusion (n=1), and undetermined etiology (n=1). No patients had hemorrhagic stroke during follow-up periods. The 1-year and 5-year successful outcomes defined as absence of atrial arrhythmias were 94.9% and 72.7%, respectively. New-onset AF was detected in 96 patients (32.8%) during the follow-up period, including 87 (90.6%) paroxysmal and 9 (9.4%) persistent AFs.

Baseline characteristics in relation to development of ischemic stroke after AFL ablation are presented in Table 1. Higher CHA₂DS₂-VASc scores, advanced age, prior history of stroke or TIA, recurrence of AFL, and occurrence of AF after ablation were significant univariate predictors for postablation stroke. In multivariate analysis, CHA₂DS₂-VASc score, relapse of AFL, and development of AF after ablation remained independent predictors for ischemic stroke after AFL ablation (Table 2).

CHA₂DS₂-VASc score for prediction of stroke after AFL ablation

CHA₂DS₂-VASc score was the strongest predictor of a stroke event after AFL ablation for a 1-point increase. The incidence of stroke increased with increases in patients' CHA₂DS₂-VASc scores (Fig. 2). ROC curves for the performance of CHA₂DS₂-VASc score in predicting incident stroke after AFL ablation were drawn. The area under the curve for the CHA₂DS₂-VASc score was 0.798 (95% CI, 0.691–0.904). A cutoff point of 2 was identified using the ROC curve (sensitivity 83.3%, specificity 67.6%) (Fig. 3). The Kaplan-Meier survival analysis revealed that the cumulative incidence of stroke after AFL ablation was higher in patient with a CHA₂DS₂-VASc score ≥2 than in those with CHA₂DS₂-VASc score <2 (14.4% vs. 1.6%, *p*<0.001) during the follow-up period (Fig. 4).

DISCUSSION

Main findings

This analysis investigated the incidence and predictors of ischemic stroke events in patients undergoing successful catheter ablation of typical AFL. By utilizing CHA₂DS₂-VASc score, the risk of stroke after AFL ablation was revealed to be correlated with the score, with an increasing trend in stroke with ascending CHA₂DS₂-VASc score. The main findings of this study were as follows: 1) the incidence of ischemic stroke after AFL ablation was 1.15 strokes per 100 person-years; 2) CHA₂DS₂-VASc score, AFL recurrence, and postablation AF were independent predictors; 3) CHA₂DS₂-VASc score was useful for stratifying the risk of stroke after catheter ablation of AFL; and 4) a CHA₂DS₂-VASc score of ≥2 was associated with higher risk of stroke following ablation.




Fig. 2. Graded increase in incidence of stroke by CHA₂DS₂-VASc score. CHA₂DS₂-VASc score, congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or transient ischemic attack score, vascular disease and sex category.

Table 2. Univariate and Multivariate Logistic Regression Analysis for Predictors of Ischemic Stroke after Catheter Ablation of AFL

Variable	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Age	1.067	1.021–1.115	0.004			
Female	0.224	0.030–1.683	0.146			
Congestive heart failure	2.313	0.531–10.066	0.264			
Hypertension	2.132	0.843–5.392	0.110			
Diabetes mellitus	2.071	0.776–5.529	0.146			
Prior stroke/TIA	7.431	2.649–20.850	<0.001			
Vascular disease	2.822	0.647–12.316	0.167			
Coronary artery disease	2.180	0.717–6.626	0.169			
LA diameter	1.065	0.989–1.146	0.097			
Recurrence of AFL	5.794	1.311–25.601	0.020	8.666	1.872–40.119	0.006
AF after AFL ablation	3.099	1.146–8.383	0.026	3.536	1.303–9.598	0.013
CHA ₂ DS ₂ -VASc score	2.091	1.593–2.746	<0.001	2.104	1.624–2.726	<0.001

AF, atrial fibrillation; AFL, atrial flutter; CHA₂DS₂-VASc score, congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or TIA score, vascular disease and sex category; CI, confidence interval; HR, hazard ratio; LA, left atrial; TIA, transient ischemic attack. To avoid collinearity, variables included in the CHA₂DS₂-VASc score were not entered into the multivariate model.

Relationship among CHA₂DS₂-VASc score and stroke after catheter ablation of AFL

In the HRS/EHRA/ECAS Consensus Statement on the continuation of anticoagulation after AF ablation, CHA₂DS₂-VASc scores or CHADS₂ are recommended for estimating stroke risk.¹² No separate statements for the management of patients with AFL exist. The CHA₂DS₂-VASc score uses the primary risk





Fig. 3. ROC curve for CHA₂DS₂-VASc score predicting ischemic stroke after AFL ablation. The AUC for CHA₂DS₂-VASc score for predicting stroke event was 0.798. At a best cutoff of 2, the sensitivity and specificity for stroke event were 83.3% and 67.6%, respectively. AUC, area under the curve; CHA₂DS₂-VASc score, congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or transient ischemic attack score, vascular disease and sex category; ROC, receiver operating characteristic.



No. at risk	Months						
	0	20	40	60	80	100	120
CHA ₂ DS ₂ -VASc < 2	189	187	187	187	186	186	186
CHA ₂ DS ₂ -VASc ≥ 2	104	98	96	93	92	90	89

Fig. 4. Stroke free survival curves for patients with different CHA₂DS₂-VASc scores. Kaplan-Meier survival analysis demonstrated that patients with a CHA₂DS₂-VASc scores ≥ 2 had a higher event rate compared with patients with a CHA₂DS₂-VASc score < 2 (14.4% vs. 1.6%, *p* < 0.001). CHA₂DS₂-VASc score, congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or transient ischemic attack score, vascular disease and sex category.

factors in the CHADS₂ scoring system, although it includes additional risk factors (65 to 74 years of age, female sex, and vascular disease) and has a broader score range. Recent studies reported that CHA₂DS₂-VASc score improved predictive ability for stroke and thromboembolism, compared to CHADS₂ score.¹⁵⁻¹⁷ There has been a marked shift in antithrombotic strategy for low-risk patients to improve outcomes by using CHA₂DS₂-VASc score. Both updated US and European clinical practice guidelines on AF recommend use of CHA₂DS₂-VASc score for assessment of stroke risk.^{11,18} The role of CHA₂DS₂-VASc score has been extended beyond its initial purpose of estimating the risk of thromboembolism in patients with nonvalvular AF. CHA₂DS₂-VASc score has been indicated to predict clinical outcomes in various conditions, including thromboembolism risk after AF ablation,¹⁹ stroke risk in patients without AF,²⁰ and left atrial thrombus risk among AFL patients.²¹ Besides, the components of the CHA₂DS₂-VASc score are associated with ischemic stroke regardless of heart rhythm. The Atherosclerosis Risk in Communities study reported that old age, hypertension, and diabetes were independent risk factor for all ischemic stroke subtypes involving cardioembolism,²² and heart failure was associated with increased risk of stroke and thromboembolism whether or not AF was present.^{23,24} In addition, patients with high CHA₂DS₂-VASc scores have been shown to have higher risk of developing AF,²⁵ which is common after successful AFL ablation^{4,26} and may contribute to subsequent ischemic stroke.^{7,27} It is logical that this scoring system may have clinical utility for risk assessment of stroke following AFL ablation. Nevertheless, in spite of these previous findings, there is little data about the relation between the CHA₂DS₂-VASc score and stroke after catheter ablation of AFL. As expected, higher CHA₂DS₂-VASc scores identified patients who are likely to develop stroke. The C statistics indicated CHA₂DS₂-VASc score had good discriminatory performance. To the best of our knowledge, this is the first study to evaluate the predictive ability of CHA₂DS₂-VASc score in assessing the risk for ischemic stroke in AFL patients who have received catheter ablation. Our results provide evidence for extending clinical value of CHA₂DS₂-VASc score to a risk stratification model for predicting stroke after typical AFL ablation.

Clinical implications

In the present cohort, over an average follow-up of 5 years after AFL ablation, ischemic strokes occurred in 6% of patients, amounting to an incidence of 1.15 strokes per 100 person-years. The stroke rate in our study was lower than what would have been expected from the natural history of chronic AFL (1.55 strokes per 100 person-years),²⁸ but higher than that of the general population (0.53 strokes per 100 person-years).²⁹ This result was consistent with those found in the earlier studies.⁷ Although patients had successful catheter ablation of typical AFL, patients were at continued risk of ischemic stroke. This raises concerns for the process of selecting patients for

continuation of antithrombotic therapy after flutter ablation. Thus, appropriate selection of patients at high risk of stroke is an important for optimal risk-based therapeutic decisions. However, previous studies did not suggest useful methods to identify patients at risk of stroke after AFL ablation. CHA₂DS₂-VASc score is composed of commonly collected clinical variables and can be applied easily in clinical practice. The present study demonstrated the ability of CHA₂DS₂-VASc score to reliably discriminate between “high-risk” and “low-risk” patients for stroke following ablation of AFL. A CHA₂DS₂-VASc score ≥ 2 identified patients with absolute risk of ischemic stroke of $>1\%$ per year. In the general AF population, an annual risk of stroke of $>1\%$ often used to identify patients in whom the benefits of long-term oral anticoagulation may outweigh the risks of bleeding.³⁰ Patients with a score ≥ 2 who have high absolute risk of stroke may benefit from continuation of anticoagulation, although randomized trial studies in direct support of this approach are still deficient. These findings may help physicians to identify patients at high risk of stroke and to perform closer follow-up after ablation. It would be reasonable to suggest that physicians make a decision about continuation of anticoagulation after AFL ablation based on the CHA₂DS₂-VASc score.

Study limitations

This study had several limitations. First, it was based on a single center experience, which could have caused site specific bias. Second, the study was performed in a cohort of predominantly male patients, which may limit generalizability. In the population-based investigation, AFL was 2.5 times more common in men than in women.³¹ However, the number of women was a fourth of those of men in this study. Third, patient follow-up was not uniform, but almost all patients underwent follow-up regularly. Fourth, the antithrombotic strategy was determined by the physicians responsible for treatment according to the individual characteristics of each patient. However, the management was based on the same principle for individuals with similar risk.

Conclusions

Patients undergoing successful catheter ablation of typical AFL remain at continued risk for ischemic stroke. CHA₂DS₂-VASc score is a useful predictor for ischemic stroke and in stratifying patients at risk of stroke after AFL ablation. This scoring system may be reliable in identifying high risk patients who may benefit from antithrombotic therapy.

ACKNOWLEDGEMENTS

This study was supported by research grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1A2B3003303, 2012R1A2A2A02045367), and grants from the Korean Healthcare Technology R&D proj-

ect funded by the Ministry of Health & Welfare (HI16C0058, HI15C1200, HI11C1606).

ORCID

Moo-Nyun Jin <https://orcid.org/0000-0001-5482-4441>
 Boyoung Joung <https://orcid.org/0000-0001-9036-7225>

REFERENCES

- Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK, et al. The natural history of lone atrial flutter. *Ann Intern Med* 2004;140:265-8.
- Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. *Am J Cardiol* 2001;87:346-9.
- Verma A, Macle L, Cox J, Skanes AC; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. *Can J Cardiol* 2011;27:60-6.
- Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. *Circ Arrhythm Electrophysiol* 2009;2:393-401.
- Chinitz JS, Gerstenfeld EP, Marchlinski FE, Callans DJ. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up. *Heart Rhythm* 2007;4:1029-33.
- Dixit S, Lavi N, Robinson M, Riley MP, Callans DJ, Marchlinski FE, et al. Noncontact electroanatomic mapping to characterize typical atrial flutter: participation of right atrial posterior wall in the re-entrant circuit. *J Cardiovasc Electrophysiol* 2011;22:422-30.
- Tomson TT, Kapa S, Bala R, Riley MP, Lin D, Epstein AE, et al. Risk of stroke and atrial fibrillation after radiofrequency catheter ablation of typical atrial flutter. *Heart Rhythm* 2012;9:1779-84.
- Moubarak G, Pavin D, Donal E, Laviolle B, Daubert JC, Mabo P. Ischemic strokes after ablation of typical atrial flutter. *Int J Cardiol* 2011;147:183-4.
- Tai CT, Chen SA, Chiang CE, Lee SH, Wen ZC, Huang JL, et al. Long-term outcome of radiofrequency catheter ablation for typical atrial flutter: risk prediction of recurrent arrhythmias. *J Cardiovasc Electrophysiol* 1998;9:115-21.
- Movsowitz C, Callans DJ, Schwartzman D, Gottlieb C, Marchlinski FE. The results of atrial flutter ablation in patients with and without a history of atrial fibrillation. *Am J Cardiol* 1996;78:93-6.
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014; 64:e1-76.
- Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Soci-

- ety (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm* 2012;9:632-96.
13. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. *Arch Neurol* 1989;46:660-2.
 14. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35-41.
 15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137:263-72.
 16. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011;342:d124.
 17. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J* 2012;33:1500-10.
 18. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33:2719-47.
 19. Chao TF, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL, et al. CHADS(2) and CHA(2)DS(2)-VAsC scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. *J Am Coll Cardiol* 2011;58:2380-5.
 20. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB; APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VAsC scores. *Heart* 2014;100:1524-30.
 21. Parikh MG, Aziz Z, Krishnan K, Madias C, Trohman RG. Usefulness of transesophageal echocardiography to confirm clinical utility of CHA2DS2-VAsC and CHADS2 scores in atrial flutter. *Am J Cardiol* 2012;109:550-5.
 22. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. *Stroke* 2006;37:2493-8.
 23. Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. *Eur J Heart Fail* 2012;14:681-95.
 24. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VAsC score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. *JAMA* 2015;314:1030-8.
 25. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, et al. The impact of risk score (CHADS2 versus CHA2DS2-VAsC) on long-term outcomes after atrial fibrillation ablation. *Heart Rhythm* 2015;12:681-6.
 26. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. *Am J Cardiol* 2009;104:671-7.
 27. Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM, Mañero MR, et al. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter. *Clin Res Cardiol* 2014;103:543-52.
 28. Wood KA, Eisenberg SJ, Kalman JM, Drew BJ, Saxon LA, Lee RJ, et al. Risk of thromboembolism in chronic atrial flutter. *Am J Cardiol* 1997;79:1043-7.
 29. Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. *JAMA* 2006;296:2939-46.
 30. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2011;4:14-21.
 31. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, et al. Incidence and predictors of atrial flutter in the general population. *J Am Coll Cardiol* 2000;36:2242-6.